Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tarceva and Avastin in metastatic renal cell carcinoma
NCT00193154Phase 2Completed
- Sponsor
- SCRI Development Innovations
- Start
- Feb 2003
- Primary completion
- Jan 2004
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of erlotinib and bevacizumab in clear cell renal cell carcinoma (ccRCC), sponsored by SCRI Development Innovations. Primary endpoint: Efficacy of the combination of Tarceva and Avastin at 18 months. Started Feb 2003; status: completed.
02
Drugs
erlotinibbevacizumab
03
Conditions
clear cell renal cell carcinoma (ccRCC)
Beyond the preview
Go deeper on NCT00193154.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00193154.